This panel brings together three leaders from industry, advocacy, and research to discuss the evolving landscape of rare disease development. They’ll highlight recent scientific breakthroughs, the growing impact of patient engagement, and strategies for translating discoveries into scalable treatments. These speakers will explore how collaboration among biotech companies, research institutions, and patient communities is accelerating progress, offering insights into the scientific, operational, and human dimensions of advancing therapies for underserved populations.

Explore how Eli Lilly’s Catalyze360 initiative is building a comprehensive platform for early-stage innovation spanning venture investment, academic partnerships, startup incubation, and translational research. This session offers founders and scientists an inside look at how Lilly identifies breakthrough science, supports emerging companies, and accelerates the path from discovery to future medicines.

This panel will explore how biotech startups are navigating today’s challenging funding environment by leveraging alternative and non-dilutive capital sources such as strategic pharma partnerships, venture philanthropy, government grants, and novel financing structures. These four investors, founders, and industry leaders will discuss when to pursue these options, how they impact company strategy, and what the future of biotech funding may hold. Join this panel if you’re an entrepreneur seeking practical insights to building resilient capital strategies beyond traditional venture capital.

Many scientists begin in academia, but the biotech ecosystem extends far beyond research and experimental design. From industry R&D and company building to venture capital, business development, and policy—where do your skills have the most impact? Join us for a candid discussion with industry leaders who successfully transitioned from academic training into the commercial ecosystem. Discover roles beyond the bench, learn how a PhD/postdoc translates into industry, and find out how to map your strengths to the future of biotechnology.

This panel will explore why women’s health is rapidly emerging as a critical and historically overlooked frontier in biotechnology, highlighting recent advances, growing investment, and the unique opportunities for innovation in areas like reproductive health and chronic conditions. These founders, investors, and scientific leaders will discuss how the field is evolving and what it will take to build successful, enduring companies that address significantly unmet needs.

Join these biotech leaders for a candid conversation that strips away the corporate jargon to explore the raw reality of navigating social impact in a high-stakes industry. This panel will dive into the hard trade-offs where purpose meets real-world execution, from pricing and partnerships to hiring and layoffs. These speakers will share personal reflections on their leadership regrets, how they leverage their corporate platforms for equitable access, and how early-career professionals can start building their own "purpose muscle" today. Ultimately, proving that mission-driven leadership isn’t a branding exercise, it is a daily series of deliberate decisions you can practice at any stage of your career.

This panel will explore the rapid evolution of next-generation mental health treatments, from psychedelic-assisted therapies to emerging neuroscience-driven approaches aimed at addressing significant unmet needs in psychiatry. These experts will discuss recent FDA breakthrough therapy designations, advances in clinical development, and the growing momentum behind novel treatments for conditions such as depression, anxiety, and other neuropsychiatric disorders. The conversation will examine the complex regulatory landscape, the science driving innovation, and the opportunities and challenges of bringing transformative mental health therapies to patients.

The most transformative biotech companies start in academic labs, but moving from discovery to market requires navigating a complex web of universities, investors, and founders. As Technology Transfer Offices (TTOs) evolve from traditional licensing centers into dynamic venture creation hubs, how is the startup landscape changing? Join us for a practical look at what happens after a discovery leaves the lab. This session brings together TTO leaders, academic founders, and commercialization experts to explore how universities are supporting entrepreneurial scientists and how the next generation of academic spinouts will be built.

This panel will explore the critical yet often overlooked role of large, standardized datasets in driving major AI breakthroughs in biology, highlighting the lack of coordinated efforts to build such resources for today’s toughest problems. It will examine the shifting incentives where startups guard data as proprietary and public datasets struggle for sustainable funding and pose the central question: who should create the next foundational biological dataset, and who will fund it? This discussion uniquely frames datasets as strategic assets that shape the future of the field, sitting at the intersection of science, capital, and policy.

This panel will explore how clinical trials are becoming a global battleground, with the U.S., Europe, and China competing to modernize infrastructure and attract biotech innovation. Speakers will discuss how regulatory reforms, rapid trial acceleration, and new technologies like decentralized models and AI are reshaping clinical development. The conversation will focus on what biotech founders need to know about navigating evolving regulations, choosing trial locations, and leveraging emerging tools to design successful clinical programs in an increasingly competitive landscape.

North Texas is quickly becoming one of the most exciting emerging ecosystems in life sciences. This panel will discuss the momentum transforming Dallas into a destination for innovation. The conversation will explore the region’s strengths in clinical care, commercialization, talent, and collaboration, in addition to what founders and investors should know about the opportunities ahead. Note: This panel will happen on August 16th at Pegasus Park which is invite-only due to capacity and interest. Email summit@nucleate.org with any questions.

This panel features Nucleate alumni founders who will share candid insights on building high-growth, science-based startups, discussing both their successes and setbacks, and offering practical lessons for early-stage scientists and aspiring entrepreneurs on turning ideas into ventures. Note: This panel will happen on August 16th at Pegasus Park which is invite-only due to capacity and interest. Email summit@nucleate.org with any questions.